Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055781 · ClinicalTrials.gov registry record · Phase 3
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
A Phase 3 study, sponsored by CTI BioPharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 311
- Enrollment target
NCT02055781: Clinical Trial Phase 3 study, sponsored by CTI BioPharma.
NCT02055781 is a Phase 3 study that was terminated before completion, run by CTI BioPharma. The registered enrollment target is 311 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02055781, a Phase 3 study, was terminated before completion, sponsored by CTI BioPharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 311 participants
- Enrollment target
Study Summary
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
Interventions
- DRUG Pacritinib
- DRUG Best Available Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2014-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02055781
The ClinicalTrials.gov registry entry for NCT02055781 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pacritinib is the first listed.
NCT02055781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02055781 about?
NCT02055781 is a clinical study titled "Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia". Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with thrombocytopenia and primary or secondary myelofibrosis.
What is the current status of trial NCT02055781?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 311 participants. The study started on 2014-02. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02055781?
The interventions under investigation include: Pacritinib (DRUG), Best Available Therapy (DRUG).
Who is sponsoring clinical trial NCT02055781?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.